Currently out of the existing stock ratings of Matthew Caufield, 155 are a BUY (89.6%), 18 are a HOLD (10.4%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield, carries an average stock price target met ratio of 29.4% that have a potential upside of 32.24% achieved within 75 days.

Matthew Caufield’s has documented 311 price targets and ratings displayed on 24 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on KOD, Kodiak Sciences at 17-Aug-2026.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on EYEN (EYENOVIA).
The best stock recommendation documented was for ALDX (ALDEYRA THE) at 3/18/2026. The price target of $2 was fulfilled within 5 days with a profit of $0.58 (40.85%) receiving and performance score of 81.69.

Average potential price target upside

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics  ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics  UBX Unity Biotechnology GMTX Gemini Therapeutics ADVM Adverum Biotechnologies DMAC DiaMedica Therapeutics KOD Kodiak Sciences OPTN OptiNose PHAT Phathom Pharmaceuticals HLVX Hillevax LENZ LENZ Therapeutics MLYS Mineralys Therapeutics, Common Stock FBLG FibroBiologics, Common Stock SRZN Surrozen IMUX Immunic AKBA Akebia Ther TARS Tarsus Pharmaceuticals  ARDX Ardelyx OYST Oyster Point Pharma

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 04-Nov-2021

$9

$7.52 (508.11%)

$9

Buy Since 30-Oct-2020

$7

$5.52 (372.97%)

$6

Buy Since 26-Jan-2015

$11

$9.52 (643.24%)

$30

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Caufield is most bullish on?

Potential upside of $32.04 has been obtained for LENZ (LENZ THERAPEUTICS)

Which stock is Matthew Caufield is most reserved on?

Potential downside of -$2.78 has been obtained for TARS (TARSUS PHARMACEUTICALS )

What Year was the first public recommendation made by Matthew Caufield?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?